Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Feb 1.

Published in final edited form as: Cancer Treat Rev. 2012 Aug 13;39(1):97–104. doi: 10.1016/j.ctrv.2012.07.002

Table 6.

Adverse Events

Outcome	Denosumab n/N	Bisphosphonates n/N	Pooled relative risk (RR)	95%CI	P value	I²
CTCAE grade 3 AE^28, ^{32-36, 42}	2,041/3,170	2,003/2,926	0.97	0.89,1.0	0.51	74%
AE-associated hospitalization^{28, 32-36, 42}	1,575/3,176	1,646/2,930	0.95	0.91,1.0	0.04	0%
AE leading to Rx discontinuation^{28, 32-36, 42}	336/3,176	402/2,942	0.82	0.72, 0.94	0.005	0%
Acute phase reactions^28, ^{32-36, 42}	264/3,170	586/2,939	0.42	0.37, 0.49	<0.00001	37.9 %
Renal toxicity^33-36	262/2,841	335/2,836	0.76	0.59, 0.98	0.03	61%
Hypocalcemia^{28, 32-36, 42}	295/3,170	143/2,926	1.9	1.6, 2.3	<0.00001	0%
New cancers^34-36	28/2,841	18/2,836	1.6	0.86, 2.8	0.14	0%
Infections^{28, 33-36}	1,474/3,125	1,646/2,930	1.0	0.93, 1.1	0.76	48%
ONJ^{32, 34-36}	52/2,885	37/2,846	1.4	0.92, 2.1	0.11	0%

AE, adverse events; Rx, treatment; ONJ, osteonecrosis of jaw.